The combination of ribociclib and letrozole achieved a 30.6% objective response rate and 84% clinical benefit rate in ...

In this systematic review and meta-analysis, researchers examined outcomes among advanced ovarian cancer patients who received interval debulking surgery compared to primary debulking surgery.

The biotech will explore the potential of BI-1808 plus Keytruda in clear cell and high-grade serous ovarian cancer subtypes.

Rising ovarian and uterine cancer rates are linked to high BMI, with disparities across sociodemographic index levels, particularly in low- and middle-SDI regions. Sarcopenia is prevalent in ...

The Pershing Square Foundation today announced the 2026 Lotus Award (formerly the Ovarian Cancer Challenge Grant), a competitive funding program to accelerate breakthrough research in ovarian cancer.

Luveltamab tazevibulin, a novel ADC, showed encouraging responses in platinum-resistant ovarian cancer, with a 32% ORR and a ...

Platinum-resistant recurrent epithelial ovarian cancer carries a bleak prognosis, with single-agent chemotherapy yielding ...

ORR for BI-1808 combined with pembrolizumab represents a meaningful improvement over pembrolizumab monotherapy in recurrent ovarian cancer (8% ORR in KEYNOTE-100)The combination demonstrated a ...

ORR for BI-1808 combined with pembrolizumab represents a meaningful improvement over pembrolizumab monotherapy in recurrent ovarian cancer (8% ORR in KEYNOTE-100)The combination demonstrated a favorab ...

“We are encouraged by the emerging data from our lung cancer programs, where systemically delivered Olvi-Vec continues to ...

Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced the publication of clinical results from the ovarian cancer cohort of its Phase 1b C-800-01 trial evaluating ...

Chennai is set to get a dedicated public women's cancer screening centre at Thousand Lights by February. The facility, being ...